Market Movers: What to Watch as Trading Kicks Off on September 29th
- Nishadil
- September 29, 2026
- 0 Comments
- 4 minutes read
- 0 Views
- Save
- Follow Topic
Morning Bell Rings: Key Stocks and Global Cues Setting the Tone for Today's Market Action
As markets open today, September 29th, investors are keenly watching global trends and a host of individual company announcements. From telecom subscriber gains to significant corporate strategic shifts, and the nuanced impact of US tariffs on the pharma sector, several stocks are poised for movement. Let's dive into the details.
Good morning, fellow investors! As we step into the trading day on September 29, 2026, the global landscape presents a somewhat mixed picture, hinting at a cautious start for Indian equities. Overnight, US markets saw a dip, with the Dow Jones, S&P 500, and Nasdaq Composite all registering losses. Our Asian counterparts are following suit, with Japan's Nikkei leading the declines. Interestingly, Gift Nifty is also showing a slight downtick, though Brent crude prices are climbing, reaching $106.9 a barrel. So, what exactly should we be keeping an eye on as the opening bell rings?
Let's start with the dynamic telecom sector, shall we? Fresh data from TRAI for August reveals some fascinating shifts in the wireless subscriber base. Reliance Jio truly dominated, adding a whopping 2.40 million new users. Not far behind, Bharti Airtel also showed strong growth, bringing in an impressive 2.11 million subscribers. Even Vodafone Idea managed to grow its base, albeit more modestly, with about 506,000 new additions. These numbers could certainly influence how these stocks perform today.
Moving on, new listings always grab attention. Today marks the debut of Varmora Granito shares on the Indian exchanges. It's worth noting that its offer was subscribed 1.58 times, receiving bids for 5.34 crore shares against the 3.39 crore on offer. How it fares post-listing will be an interesting watch for investors looking at new opportunities.
Several companies have made significant strategic announcements. Ola Electric, for instance, has just received board approval for a rights issue to raise a substantial ₹1,000 crore through partly paid-up equity shares. This follows earlier indications of a larger fundraising push, so clearly, growth remains a top priority. Then there's the Tata Group, which always stirs headlines. Tata Trusts has unveiled a strategic reorganisation plan for Tata Sons, proposing a return to its older operational structure. This move, if it materializes, could potentially negate the need for a stock market listing for Tata Sons, a development many have been speculating about for a while.
In the world of funding and sustainability, Clean Max Enviro Energy recently secured ₹2,500 crore through green debt securities via a private placement. This kind of capital infusion for sustainable projects is a positive sign for the renewable energy space and could bring attention to other players in the sector.
A quick glance at regulatory matters shows that four Adani group companies, along with chairman Gautam Adani and 13 others, have settled proceedings with SEBI. They paid a cumulative sum of ₹1.48 crore under settlement regulations. This development might help clear some lingering uncertainties around the group for investors.
Now, for a crucial update from the pharmaceutical sector, which often feels the winds of international policy. There's a bit of a mixed bag here with the US Commerce Department's recent announcements. On one hand, it's positive news for Indian pharma that the US will not levy ad valorem tariffs on certain specialty drugs and their associated ingredients, especially those for rare medical conditions, imported from India and 19 other countries. This list was published in the Federal Register. However, a separate development indicates that the US is also gearing up to impose a significant 100 percent tariff on certain patented pharmaceutical imports and their associated ingredients, effective from today, September 29th. Indian pharma companies need to navigate these dual announcements carefully.
Within the pharma space, Natco Pharma has increased its proposed investment in US-based eGenesis Inc. to $16.70 million (around ₹139 crore) from an earlier $14 million, signaling confidence in the biotechnology firm. Zydus Lifesciences also made headlines after the USFDA completed a cGMP inspection at its Ahmedabad plant, which concluded with just one observation – generally seen as a favorable outcome.
Finally, a few other notable updates: Coforge has appointed Akhil Gupta as its Non-Executive Independent Director and Chairperson for a five-year term starting today, September 29th. Radico Khaitan is taking its Indian luxury spirits portfolio to four major UK airports, which is quite an expansion. And ITC has bolstered its hold on Sproutlife, acquiring an additional 13,445 equity shares, now giving it full 100 percent ownership of the company. These individual stories, combined with the broader market sentiment, will certainly make for an eventful trading session.
- India
- Business
- News
- BusinessNews
- AdaniGroup
- IndianStockMarket
- MarketOutlook
- ZydusLifesciences
- OlaElectric
- GlobalCues
- StocksInFocus
- BuzzingStocks
- VodafoneIdea
- UsTariffs
- PharmaStocks
- StocksToWatch
- GiftNifty
- StocksToWatchToday
- BhartiAirtel
- RelianceJio
- Itc
- Coforge
- TataGroup
- StocksInNews
- PreMarketSetup
- TraiData
- NatcoPharma
- RadicoKhaitan
- TataStocks
- GreenDebt
- TrumpTariffsOnPharma
- September29th
- VarmoraGranito
Editorial note: Nishadil may use AI assistance for news drafting and formatting. Readers can report issues from this page, and material corrections are reviewed under our editorial standards.